KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

被引：2
|
作者：
Yu, Evan Y.
Piulats, Josep M.
Gravis, Gwenaelle
Laguerre, Brigitte
Arija, Jose Angel Arranz
Oudard, Stephane
Fong, Peter C. C.
Kolinsky, Michael Paul
Augustin, Marinela
Feyerabend, Susan
Kam, Audrey E.
Gurney, Howard
Tafreshi, Ali
Retz, Margitta
Berry, William R.
Mar, Nataliya
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
De Bono, Johann S.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Catalan Inst Oncol, Barcelona, Spain
[3] CLCC Inst Paoli Calmettes, Paris, France
[4] Ctr Eugene Marquis, Rennes, France
[5] Hosp Gregorio Maranon, Madrid, Spain
[6] Hop Europeen Georges Pompidou, Paris, France
[7] Auckland City Hosp, Auckland, New Zealand
[8] Cross Canc Inst, Edmonton, AB, Canada
[9] Paracelsus Med Univ, Nurnberg, Germany
[10] Studienpraxis Urol, Nurtingen, Germany
[11] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[12] Macquarie Univ Hosp, Sydney, NSW, Australia
[13] Univ Wollongong, Wollongong, NSW, Australia
[14] Tech Univ Munich, Rechts Isar Univ Hosp, Munich, Germany
[15] Duke Canc Ctr Cary, Cary, NC USA
[16] UCI Hlth, Orange, CA USA
[17] Merck & Co Inc, Kenilworth, NJ USA
[18] Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
100
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update
    Romano, E.
    Sridhar, S. S.
    Kolinsky, M. P.
    Gravis, G.
    Mourey, L.
    Piulats, J. M.
    Berry, W. R.
    Gurney, H.
    Retz, M.
    Appleman, L. J.
    Boegemann, M.
    de Bono, J. S.
    Joshua, A. M.
    Emmenegger, U.
    Conter, H. J.
    Laguerre, B.
    Wu, H.
    Qiu, P.
    Schloss, C.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S512 - S513
  • [12] KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Berry, William R.
    Fong, Peter C. C.
    Piulats, Josep M.
    Appleman, Leonard Joseph
    Conter, Henry Jacob
    Feyerabend, Susan
    Shore, Neal D.
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Gurney, Howard
    Retz, Margitta
    Romano, Emanuela
    Mourey, Loic
    De Bono, Johann S.
    Kam, Audrey E.
    Emmenegger, Urban
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [13] Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update
    Mourey, L.
    Conter, H. J.
    Shore, N.
    Berry, W. R.
    Fong, P. C.
    Piulats, J. M.
    Appleman, L. J.
    Todenhoefer, T.
    Gravis, G.
    Laguerre, B.
    Gurney, H.
    Retz, M.
    Romano, E.
    de Bono, J. S.
    Kam, A. E.
    Emmenegger, U.
    Wu, H.
    Qiu, P.
    Schloss, C.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S516 - S517
  • [14] Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.
    Sridhar, Srikala S.
    Kolinsky, Michael Paul
    Gravis, Gwenaelle
    Mourey, Loic
    Rodriguez, Jose Maria M. Piulats
    Romano, Emanuela
    Berry, William R.
    Gurney, Howard
    Retz, Margitta
    Appleman, Leonard Joseph
    Boegemann, Martin
    De Bono, Johann S.
    Joshua, Anthony M.
    Emmenegger, Urban
    Conter, Henry Jacob
    Laguerre, Brigitte
    Wu, Haiyan
    Qiu, Ping
    Schloss, Charles
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [15] Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
    Massard, Christophe
    Retz, Margitta
    Hammerer, Peter
    Quevedo, Fernando
    Fong, Peter C. C.
    Berry, William R.
    Gurney, Howard
    Piulats, Josep M.
    Joshua, Anthony
    Linch, Mark David
    Kolinsky, Michael
    Romano, Emanuela
    Sridhar, Srikala S.
    Conter, Henry Jacob
    Augustin, Marinela
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [16] PEMBROLIZUMAB PLUS ENZALUTAMIDE IN ABIRATERONE-PRETREATED PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: UPDATED RESULTS FROM KEYNOTE-365 COHORT C
    Yu, Evan Y.
    Fong, Peter
    Piulats, Josep M.
    Appleman, Leonard
    Conter, Henry
    Feyerabend, Susan
    Shore, Neal
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Gurney, Howard
    Retz, Margitta
    Romano, Emanuela
    Mourey, Loic
    de Bono, Johann S.
    Kam, Audrey
    Emmenegger, Urban
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian
    Berry, William
    JOURNAL OF UROLOGY, 2020, 203 : E368 - E368
  • [17] Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
    Fong, Peter C. C.
    Retz, Margitta
    Drakaki, Alexandra
    Massard, Christophe
    Berry, William R.
    Romano, Emanuela
    De Bono, Johann S.
    Feyerabend, Susan
    Appleman, Leonard Joseph
    Conter, Henry Jacob
    Sridhar, Srikala S.
    Shore, Neal D.
    Linch, Mark David
    Joshua, Anthony
    Gurney, Howard
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [18] Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.
    Conter, Henry Jacob
    Shore, Neal D.
    Berry, William R.
    Fong, Peter C. C.
    Rodriguez, Jose Maria M. Piulats
    Appleman, Leonard Joseph
    Todenhoefer, Tilman
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Gurney, Howard
    Retz, Margitta
    Romano, Emanuela
    Mourey, Loic
    De Bono, Johann S.
    Kam, Audrey E.
    Emmenegger, Urban
    Wu, Haiyan
    Qiu, Ping
    Schloss, Charles
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [19] Update on KEYNOTE-199, cohorts 1-3: Pembrolizumab (pembro) for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC)
    Antonarakis, Emmanuel S.
    Piulats, Josep M.
    Gross-Goupil, Marine
    Goh, Jeffrey C.
    Vaishampayan, Ulka N.
    De Wit, Ronald
    Alanko, Tuomo
    Fukasawa, Satoshi
    Tabata, Kenichi
    Feyerabend, Susan
    Berger, Raanan
    Wu, Helen
    Kim, Jeri
    Schloss, Charles
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [20] Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis
    Yu, E.
    Piulats, J. M.
    Gravis, G.
    Fong, P.
    Todenhoefer, T.
    Laguerre, B.
    Arranz, J.
    Oudard, S.
    Massard, C.
    Stoeckle, M.
    Nordquist, L. T.
    Carles, J.
    Huang, M.
    Li, Y.
    Qiu, P.
    Poehlein, C. H.
    Schloss, C.
    de Bono, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S387 - S387
12345